Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
Michelle Meyer, … , Peter L. Collins, Alexander Bukreyev
Michelle Meyer, … , Peter L. Collins, Alexander Bukreyev
Published August 3, 2015; First published July 13, 2015
Citation Information: J Clin Invest. 2015;125(8):3241-3255. https://doi.org/10.1172/JCI81532.
View: Text | PDF
Categories: Research Article Vaccines

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses

  • Text
  • PDF
Abstract

Direct delivery of aerosolized vaccines to the respiratory mucosa elicits both systemic and mucosal responses. This vaccine strategy has not been tested for Ebola virus (EBOV) or other hemorrhagic fever viruses. Here, we examined the immunogenicity and protective efficacy of an aerosolized human parainfluenza virus type 3–vectored vaccine that expresses the glycoprotein (GP) of EBOV (HPIV3/EboGP) delivered to the respiratory tract. Rhesus macaques were vaccinated with aerosolized HPIV3/EboGP, liquid HPIV3/EboGP, or an unrelated, intramuscular, Venezuelan equine encephalitis replicon vaccine expressing EBOV GP. Serum and mucosal samples from aerosolized HPIV3/EboGP recipients exhibited high EBOV-specific IgG, IgA, and neutralizing antibody titers, which exceeded or equaled titers observed in liquid recipients. The HPIV3/EboGP vaccine induced an EBOV-specific cellular response that was greatest in the lungs and yielded polyfunctional CD8+ T cells, including a subset that expressed CD103 (αE integrin), and CD4+ T helper cells that were predominately type 1. The magnitude of the CD4+ T cell response was greater in aerosol vaccinees. The HPIV3/EboGP vaccine produced a more robust cell-mediated and humoral immune response than the systemic replicon vaccine. Moreover, 1 aerosol HPIV3/EboGP dose conferred 100% protection to macaques exposed to EBOV. Aerosol vaccination represents a useful and feasible vaccination mode that can be implemented with ease in a filovirus disease outbreak situation.

Authors

Michelle Meyer, Tania Garron, Ndongala M. Lubaki, Chad E. Mire, Karla A. Fenton, Curtis Klages, Gene G. Olinger, Thomas W. Geisbert, Peter L. Collins, Alexander Bukreyev

×

Figure 1

Schedules of vaccinations, biosamplings, and EBOV exposure.

Options: View larger image (or click on image) Download as PowerPoint
Schedules of vaccinations, biosamplings, and EBOV exposure.
(A) Study 1:...
(A) Study 1: NHP immune response to vaccination. Groups of rhesus macaques were vaccinated with HPIV3/EboGP as an aerosol (n = 4; green) or a liquid via the i.n./i.t. (n = 4; red) route, the empty HPIV3 vector control (n = 2; black), or the VRP vaccine by the i.m. route (n = 4; blue). Twenty-eight days after the first dose, all NHPs received a second dose of their respective vaccine. On day 56, NHPs were euthanized and mononuclear cells were extracted. (B) Study 2: testing of protective efficacy. Groups of rhesus macaques were vaccinated with 1 (n = 4; purple) or 2 doses (n = 4; green) of aerosolized HPIV3/EboGP, 2 doses of liquid HPIV3/EboGP (n = 2; red), or HPIV3 control (n = 2; black). Fifty-five days after vaccination, NHPs were infected with EBOV. At the end of the study, surviving animals were euthanized and terminal bleed samples were collected. Over the course of the 2 studies, serum and BAL samples were collected on indicated days.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts